INTRODUCTION
============

Cytokinesis in animal and fungal cells requires spatiotemporally coordinated functions of a contractile actomyosin ring (AMR) and targeted membrane deposition. The AMR is believed to power the ingression of the plasma membrane (PM) at the division site and guide membrane deposition ([@B1]; [@B12]; [@B35]), whereas membrane deposition is believed to increase surface area, as well as deliver enzymatic cargoes for localized extracellular matrix (ECM) remodeling during cytokinesis ([@B41]; [@B2]; [@B12]). The core components of the AMR and the membrane‑trafficking machine are conserved from yeast to human ([@B1]; [@B35]). Thus the budding yeast *Saccharomyces cerevisiae* has served as an effective model for elucidating the general mechanisms of cytokinesis.

ECM remodeling appears to play a critical role in animal cytokinesis, as evidenced by the cytokinesis failure caused by a defect in chondroitin synthesis in *Caenorhabditis elegans* and mice ([@B29]; [@B18]). However, it remains unknown how ECM is remodeled specifically at the division site and how this process is regulated by the cell cycle machinery. In budding yeast, the primary septum (PS), a specialized cell wall structure that is synthesized by the chitin synthase Chs2 during cytokinesis ([@B37]), is conceptually similar to animal ECM. Deletion of *CHS2* causes severe defects in cytokinesis, including rapid and asymmetric AMR constriction, which underscores the importance of ECM remodeling during yeast cytokinesis ([@B3]; [@B38]; [@B46]). Deletion of *MYO1*, which encodes the sole myosin‑II in budding yeast, also causes defects in cytokinesis and cell separation, including misoriented PS formation ([@B12]). Thus PS formation and AMR constriction are mutually dependent ([@B3]; [@B38]; [@B46]), suggesting that these processes are normally coordinated to ensure efficient cytokinesis.

How PS formation is regulated by cell cycle signals remains poorly understood. During mitosis, Chs2 is synthesized and held at the endoplasmic reticulum (ER) through phosphorylation by CDK1 ([@B8]; [@B49]; [@B42]). At the onset of cytokinesis, Chs2 is triggered to exit the ER by the mitotic exit network (MEN; [@B49]; [@B42]; [@B7]) and is then delivered to the division site (or the bud neck) via the secretory pathway ([@B8]; [@B46]). MEN consists of a Ras‑related small GTPase (Tem1), protein kinases (Cdc15, Dbf2, and its homologue Dbf20), a protein phosphatase (Cdc14), and a few regulatory proteins ([@B1]; [@B40]). GTP‑bound Tem1 binds and recruits Cdc15 to the spindle pole bodies (SPBs; equivalent of centrosomes in animal cells), which, in turn, recruits and activates Dbf2, resulting in the release of Cdc14 from the nucleolus to the entire cell. Cdc14 then acts on a few key substrates to down‑regulate CDK1/mitotic cyclin activity, resulting in mitotic exit. Cdc14 also directly acts on Chs2 to remove the phosphorylation by CDK1, which enables Chs2 exit from the ER for subsequent transport to the division site ([@B7]). MEN may also regulate cytokinesis directly at the division site, as several MEN components, including the Cdc15 and Dbf2 kinases, localize to the division site during cytokinesis ([@B14]; [@B48]). However, the cytokinesis targets of these kinases are largely unknown. In this study, we demonstrate that Dbf2 regulates PS formation directly by phosphorylating Chs2 at a single residue, resulting in its dissociation from the AMR during late stage of cytokinesis, and that timed phosphorylation of this residue is important for PS formation during cytokinesis.

Several proteins, including Iqg1 (the sole IQGAP in budding yeast), Inn1, Hof1 (a F‑BAR protein), and Cyk3 have been implicated in PS formation ([@B19]; [@B45]; [@B33]; [@B28]), but the underlying mechanism remains unknown. Iqg1 is also required for actin ring assembly ([@B11]; [@B21]). Of interest, overexpression of Cyk3 suppresses the lethality and cytokinesis defects of *iqg1∆* cells without restoring actin ring assembly, suggesting that Cyk3 functions in an AMR‑independent process---most likely septum formation---to promote cytokinesis ([@B19]). Overexpression of Cyk3 also suppresses the cytokinesis and PS defects of *inn1∆* cells ([@B33]) and causes the formation of ectopic PS‑like structures in wild‑type cells ([@B28]). These observations suggest that Cyk3 may be an activator of Chs2. In this study, we show that overexpression of Cyk3 robustly suppresses the growth and cytokinesis defects of the *chs2* phosphomutants, further supporting the "activator" hypothesis. We also demonstrate that Cyk3 and Dbf2 phosphorylation define distinct mechanisms in regulating Chs2 function during cytokinesis.

RESULTS
=======

Chs2 is a direct substrate of Dbf2 kinase in vitro
--------------------------------------------------

The following observations suggest that Chs2 may be a substrate of Dbf2 during cytokinesis. First, both Chs2 and Dbf2 localize to the division site during cytokinesis, although their precise timing of arrival has not been determined ([@B8]; [@B14]). Second, Chs2 is essential for PS formation ([@B37]; [@B39]), whereas Dbf2 has also been implicated in the process ([@B17]; [@B28]). Finally, deletion analyses and in vitro chitin synthase assays suggest that an N‑terminal region, especially residues 197--230, of Chs2, which is located outside the catalytic domains (con1 and con2), plays an ill‑defined regulatory role in its activation ([Figure 1A](#F1){ref-type="fig"}; [@B44]), and this region contains two consensus sequences (RXXS) for Dbf2 ([@B24]), with serines 217 and 225 as the potential phosphorylation sites ([Figure 1A](#F1){ref-type="fig"}). To determine whether Dbf2 can phosphorylate Chs2 directly, we fused the N-terminal region (residues 1--286) of Chs2 to glutathione *S*-transferase (GST), and subjected the fusion protein to in vitro kinase assay using recombinant Dbf2-Mob1 kinase (Mob1 is the regulatory subunit for Dbf2), which was preactivated by Cdc15 ([@B25]). Chs2 was robustly phosphorylated by preactivated Dbf2 but not by Cdc15 alone or its combination with an inactive Dbf2 ([Figure 1B](#F1){ref-type="fig"}, left). Change of Ser-217 to alanine (S217A) decreased the phosphorylation to 73% of the wild‑type level ([Figure 1, B and C](#F1){ref-type="fig"}). Additional change of Ser-225 to alanine (S217A, S225A) further reduced the phosphorylation to 43% ([Figure 1, B and C](#F1){ref-type="fig"}). These data indicate that Chs2 is a direct substrate of Dbf2 in vitro and that both Ser-217 and Ser-225 are phosphorylated by Dbf2. Of importance, the same two sites were also found to be phosphorylated in vivo in studies aimed at global mapping of phosphoproteins in budding yeast, but the responsible kinase was not known ([@B6]; [@B10]).

![Mitotic exit kinase Dbf2 directly phosphorylates Chs2. (A) Schematic diagram of Chs2. con1 and con2, conserved regions of typical chitin synthases; TM, predicted transmembrane domains. Demonstrated and putative phosphorylation sites for CDK1 and Dbf2 kinases in the N‑terminal region of Chs2 are indicated. (B) In vitro phosphorylation of the N‑terminal region of Chs2 by Dbf2. Asterisk, degradation product of GST-Chs2 (1--286). (C) Quantification of Dbf2-mediated phosphorylation of Chs2. (D) Time-lapse analysis of a yeast cell coexpressing Chs2-GFP and Dbf2-mCherry (YO1182). Cells were grown in SC-HIS media to exponential phase at 25°C and then processed for time‑lapse microscopy. Arrows, spindle pole bodies. Scale bar, 2 μm.](2445fig1){#F1}

Chs2 localizes to the division site before Dbf2 during cytokinesis
------------------------------------------------------------------

To determine when and where Dbf2 might phosphorylate Chs2 during cytokinesis, we performed live‑cell imaging on cells carrying both Chs2‑GFP and Dbf2‑mCherry. As expected, Chs2 was localized to the mother‑bud neck of cells at the onset of cytokinesis ([Figure 1D](#F1){ref-type="fig"} and Supplemental Video S1; [@B38]; [@B12]). Consistent with a previous observation ([@B14]), Dbf2 was first localized to the spindle pole bodies ([Figure 1D](#F1){ref-type="fig"}, arrows) and then translocated to the bud neck during cytokinesis. Of importance, we found that the bulk of Dbf2 arrived at the neck 4 min after Chs2 ([Figure 1D](#F1){ref-type="fig"} and Supplemental Video S1). Chs2 was generally removed from the neck region by endocytosis within 10 min after its arrival, whereas Dbf2 remained at the neck for longer time ([Figure 1D](#F1){ref-type="fig"}). On the basis of our previous ([@B12]; [@B47]) and present (see [Figure 4D later in the paper](#F4){ref-type="fig"}) studies, during the first 4 min of Chs2 localization, the AMR would have constricted \>50% of its initial size. Thus Dbf2 likely phosphorylates Chs2 at the neck region during late stage of cytokinesis. Of interest, the bulk accumulation and maintenance of Dbf2 at the neck appear to correlate with the onset of Chs2 endocytosis, which is marked by the appearance of Chs2--green fluorescent protein (GFP) "puncta" near the neck region.

![Both phosphorylation and dephosphorylation of Ser-217 are important for cell growth and division. (A) Tenfold serial dilutions of different strains (YO1338, YO1339, YO1359, YO1360, YO1450, and YO1451) containing pRS305 (Vector) or its derivatives carrying different *Chs2\*-GFP* alleles integrated at the *leu2* locus of a parent strain (*chs2∆ CDC3-mCherry*) were spotted onto plates containing either minimal medium (SC‑LEU) or rich medium (YPD) and grown for 2--3 d at 25°C. (B) Strains indicated in A were grown to exponential phase in liquid SC-LEU or rich (YM-1) media at 25°C. Percentages of cell clusters (counted \>200 cells for each strain under each growth condition) were analyzed as indicated. (C) Representative morphologies of strains (YO1338, YO1339, YO1450, and YO1451) were visualized by DIC microscopy after grown exponentially in SC-LEU and YM-1 media at 25°C. Scale bar, 5 μm.](2445fig2){#F2}

![Phosphorylation and dephosphorylation of Ser-217 affect chitin synthesis at the division site. (A) Cells (YO1320, YO1324, and YO1325; *chs1∆ chs2∆ chs3∆* with YCp111-Chs2\*-GFP plasmids) were grown in SC-LEU medium to exponential phase at 25°C and then diluted into rich media (YM-1) and grown for additional 3 h at 25°C. Chs2\*‑GFP and cellular chitin (stained with 10 mg/ml Calcofluor) were visualized by fluorescence microscopy. (B) Quantification of chitin synthesis in vivo. The ratio of Calcofluor staining intensity divided by Chs2\*-GFP signal intensity was plotted for each indicated strain (WT, n = 21; S217A, n = 21; S217D, n = 26). The error bar represents SEM. \*p \< 0.001 in comparison to WT. (C) Cells (YO1535, YO1536, and YO1537; *chs1∆ chs3∆* with YEp-pGAL1-HA3-Chs2\* plasmid \[*2 μ*, *TRP1*\]) were grown in inducing medium (yeast nitrogen base containing 2% galactose and 1% raffinose) for 18 h at 25°C. In vitro chitin synthase II activity was measured with and without prior treatment of portions of membranes with 0, 100, and 200 μg of trypsin. Scale bar, 2 μm.](2445fig3){#F3}

![Chs2-S217A and Chs2-S217D display distinct dynamic behaviors during cytokinesis. (A) Localization patterns of Chs2-S217A and Chs2-S217D during the cell cycle. Cells of different strains (YO1339, YO1359, and YO1360; *chs2∆ CDC3-mCherry* with integrated *Chs2\*-GFP* in at the *leu2* locus) were grown in SC-LEU medium to exponential phase at 25°C and then diluted into rich media (YM-1) and grown for additional 1--2 h at 25°C before being subjected to time‑lapse analysis. (B) Three‑dimensional reconstruction of selected time points for the cells shown in A. Both the side view (top) and the en face view (bottom) of the cells are presented. The blue arrow and dashed line indicate the direction of rotation. White arrow indicates the position of Chs2\*‑GFP near the end of its constriction. Scale bar, 1 μm. (C) Data acquired in A were quantified for the constriction patterns of Chs2-S217A and Chs2-S217D (WT, n = 22; S217A, n = 29; S217D, n = 41). (D) Spatial relationship between Chs2-S217A or Chs2-S217D and the actomyosin ring during cytokinesis. Cells of different strains (YO1454, YO1453, and YO1455; *chs2∆ Chs2\*-GFP::LEU2* with pRS314‑MYO1-C-mCherry) were cultured and imaged as in A. Arrowhead indicates the onset of AMR constriction. (E) Quantification of the durations of Chs2\*-GFP, AMR contraction, and AMR disassembly during cytokinesis (WT, n = 16; S217A S225A, n = 17; S217D S225D, n = 29).](2445fig4){#F4}

Both phosphorylation and dephosphorylation of Ser-217 are important for cytokinesis
-----------------------------------------------------------------------------------

To determine the functional consequence of Ser-217 and Ser-225 phosphorylation, C‑terminally *GFP*‑tagged, wild‑type, phosphodeficient (*chs2-S217A*, *chs2‑S225A*, *chs2-AA* \[*S217A S225A*\]) and phosphomimic (*chs2-S217D*, *chs2‑S225D*, *chs2-DD* \[*S217D S225D*\]) alleles of *CHS2*, expressed from the native *CHS2* promoter, were integrated onto the chromosome of *chs2Δ* cells, respectively. None of the *chs2* phosphomutants displayed obvious defects in cell growth or cytokinesis when cultured in minimal media ([Figure 2, A](#F2){ref-type="fig"}, left, and [B](#F2){ref-type="fig"}, left). However, both *chs2‑S217A* and *chs2‑S217D* mutants displayed clear defects in cell growth and cytokinesis when grown in rich media ([Figure 2, A](#F2){ref-type="fig"}, right, and [B](#F2){ref-type="fig"}, right). Forty-four percent of *chs2‑S217A* and 53% *chs2‑S217D* cells formed cell clusters containing three or more cell bodies, indicative of a cytokinesis defect. In comparison, none of the wild‑type cells and 66% of the *chs2Δ* cells formed cell clusters. Neither *chs2‑S225A* nor *chs2‑S225D* mutation caused any obvious defects in cell growth and cytokinesis even in rich media (unpublished data). In addition, the *chs2‑S225* mutations only slightly enhanced the phenotypes of the *chs2‑S217* mutations ([Figure 2, A](#F2){ref-type="fig"}, right, and [B](#F2){ref-type="fig"}, right). Together these data indicate that both phosphorylation and dephosphorylation of Ser-217 are important for cytokinesis.

It is not clear why the *chs2‑S217* mutants displayed media‑dependent behavior. However, media influence on the phenotypes of yeast cytokinesis mutants has been observed ([@B5]; [@B33]). It is possible that the *chs2‑S217* mutations have compromised the functionality of Chs2 at the division site to the extent that is still sufficient to support cytokinesis in slow‑growing minimal media but not in fast‑growing rich media. Because of the media influence, only cells grown in rich media were used for functional assays on Chs2 hereafter, unless stated otherwise.

Phosphoregulation of Chs2 is important for chitin synthesis at the division site
--------------------------------------------------------------------------------

To explore the underlying mechanism for the cytokinesis defect caused by the *chs2‑S217* mutations, we first monitored the chitin level at the division site in different strains by Calcofluor staining ([@B36]). C‑terminally *GFP*‑tagged alleles of *CHS2* (wild‑type, *S217A*, and *S217D*) under control of the native promoter and carrying a centromere‑based plasmid were introduced into a *chs1Δ chs2Δ chs3Δ* strain in which all chitin synthase genes in budding yeast had been deleted. The viability of the triple mutant relied solely on the introduced *chs2* allele. The chitin levels at the division site of the *chs2‑S217A* and *chs2‑S217D* cells were both reduced to ∼71% of the wild‑type level ([Figure 3, A and B](#F3){ref-type="fig"}). To ensure fair comparisons, only cells with a similar size of Chs2\*‑GFP ring from different strains ([Figure 3A](#F3){ref-type="fig"}), which is indicative of a similar cell cycle stage, were included in our quantitation. These data suggest that phosphoregulation of Chs2 at Ser-217 is important for chitin synthesis at the division site, which may account for the cytokinesis defects caused by these mutations.

The decreased chitin synthesis at the division site could ensue as a result of decreased catalytic activity and/or altered protein expression, localization, or dynamics. To distinguish these possibilities, we first measured the chitin synthase activity of the Chs2 variants in strains lacking chitin synthase I and chitin synthase III activity. Chitin synthase II assays were done using membranes from *chs1∆ chs3∆* rather than *chs1∆ chs2∆ chs3∆* cells because the former are much healthier in growth and division ([@B39]). Furthermore, the activity of chromosomally encoded Chs2 in membranes from *chs1∆ chs3∆* cells grown in minimal medium is negligible ([@B32]), regardless of pretreatment with trypsin, which is known to stimulate Chs2 activity in vitro ([@B37]; [@B44]). High‑copy plasmids expressing HA3-Chs2, HA3-Chs2-S217A, or HA3-Chs2-S217D from the inducible *GAL1* promoter were introduced into *chs1∆ chs3∆* cells, which were then grown in minimal medium and induced by the addition of galactose. Membranes from each strain were assayed for chitin synthase activity with or without prior treatment by trypsin and proved to have high activity ([Figure 3C](#F3){ref-type="fig"}), whereas membranes from *chs1∆ chs3∆* cells assayed in parallel incorporated background levels of radioactivity regardless of trypsin treatment (unpublished data). Trypsin treatment stimulated chitin synthase activities of all Chs2 variants to a similar extent (1.5- to 2-fold). Specific activities of membranes expressing Chs2 and Chs2-S217A were comparable, whereas the specific activity of the membranes expressing Chs2-S217D was on average ∼80% of that expressing Chs2. Similar results were obtained when cells were grown in rich medium (unpublished data). These data suggest that the defect in cytokinesis or chitin synthesis at the division site caused by the *chs2‑S217* mutations may not be fully explained by the mildly decreased catalytic activity of the mutant proteins assayed at 2 mM UDP-GlcNAc.

Phosphorylation of Ser-217 regulates Chs2 dynamics at the division site
-----------------------------------------------------------------------

To further explore the underlying mechanism for the cytokinesis defect, we monitored the dynamics of Chs2‑S217A and Chs2‑S217D proteins at the division site. Yeast strains carrying Cdc3‑mCherry and different *GFP*‑tagged alleles of *CHS2* (*CHS2*, *chs2‑S217A*, and *chs2‑S217D* as the sole source of Chs2 in the cell) were grown in rich media and imaged by three‑dimensional spin‑disk time‑lapse microscopy. Like wild-type Chs2-GFP, both Chs2-S217A-GFP and Chs2-S217D-GFP were localized to the bud neck around the onset of cytokinesis ([@B12]), which is marked by the splitting of the septin hourglass into two cortical rings (Cdc3‑mCherry; [Figure 4A](#F4){ref-type="fig"}; [@B22]). The duration of Chs2-S217A-GFP and Chs2-S217D-GFP at the division is 12.8 ± 2.4 and 11.5 ± 2.0 min, respectively, slightly longer than the 10.3 ± 1.0 min for wild‑type Chs2‑GFP. It is striking that Chs2-S217A-GFP constricted asymmetrically in 79% of cells ([Figure 4, B and C](#F4){ref-type="fig"}, and Supplemental Video S2, middle), in comparison to 100% symmetric constriction for wild‑type Chs2‑GFP (Supplemental Video S2, left); in contrast, Chs2-S217D-GFP showed little or no constriction before its disappearance from the division site in 80% of cells (Supplemental Video S2, right). As expected, the AMR (marked by the mCherry‑tagged sole myosin‑II, Myo1, in budding yeast) and Chs2‑GFP always constricted together and symmetrically in wild‑type cells ([Figure 4D](#F4){ref-type="fig"} and Supplemental Video S3, left; [@B12]). Similarly, the AMR and Chs2‑AA‑GFP always constricted together but in an asymmetric manner (Supplemental Video S3, middle). In contrast, Chs2‑DD‑GFP failed to follow the constriction of the AMR (Supplemental Video S3, right), suggesting the uncoupling of this mutant Chs2 from the AMR. AMR constriction and disassembly appeared to be slightly longer in both Ser-217 mutants, especially in the *chs2‑AA* mutant, than in wild‑type cells ([Figure 4E](#F4){ref-type="fig"}).

The uncoupling of Chs2‑S217D from the AMR is further supported by the following observations. First, despite similar profiles in protein expression (unpublished data) and the timing and duration of their localizations, Chs2‑S217D‑GFP always appeared as a broad and nonconstricting band, whereas the wild‑type Chs2‑GFP or Chs2‑S217A‑GFP appeared as a sharply focused and constricting band between the septin rings. Second, fluorescence recovery after photobleaching (FRAP) analysis indicates that wild‑type Chs2‑GFP at the division site recovers quickly after bleaching during the first ∼3 min of its localization, presumably reflecting a continuous recruitment to the division site. Chs2‑GFP is then immobilized in a myosin II--dependent manner for the rest of cytokinesis, ∼6--7 min. Using this analysis on cells with already localized Chs2 and photobleaching only a portion of the Chs2\*‑GFP ring, we found that Chs2‑S217D‑GFP displayed full recovery throughout cytokinesis (Supplemental Video S4, right); in contrast, wild‑type Chs2‑GFP (Supplemental Video S4, left) and the majority of Chs2‑S217A‑GFP (Supplemental Video S4, middle) displayed no or little recovery ([Figure 5, A and B](#F5){ref-type="fig"}). Taken together, these data suggest that phosphorylation of Chs2 by Dbf2 may trigger its dissociation from the AMR during the late stage of cytokinesis.

![Phosphomimic Chs2-S217D is highly mobile during cytokinesis. (A) FRAP analysis of Chs2‑S217A and Chs2‑S217D. Cells of different strains (YO1339, YO1359, and YO1360; *chs2∆ CDC3-mCherry* with integrated *Chs2\*-GFP* at the *leu2* locus) were grown in SC-LEU to exponential phase at 23°C and then diluted into rich YM-1 medium and grown for at least 3 additional hours before being subjected to FRAP analysis. (B) Data acquired in A were quantified for the recovery patterns of Chs2\*-GFP (WT, n = 12; S217A, n = 28; S217D, n = 18). Arrows indicate the points of photobleaching.](2445fig5){#F5}

Inactivation of Dbf2 causes delayed endocytic removal of Chs2 from the division site
------------------------------------------------------------------------------------

If Chs2 were indeed a physiological substrate of Dbf2 at the division site, Chs2 would be expected to display asymmetric constriction, essentially phenocopying the *chs2‑S217A* mutant, when Dbf2 is inactivated. To test this hypothesis, we monitored at the nonpermissive temperature Chs2‑GFP localization in a wild‑type strain and a *dbf2*‑Ts (temperature‑sensitive) mutant carrying a *GAL1* promoter--controlled allele of *SIC1^s^ (T5V, T33V, S76A)* that encodes a stable version of the CDK1 inhibitor ([@B28]). Because Dbf2 inactivation simultaneously blocks both mitotic exit and cytokinesis, Sic1 overexpression was induced by adding galactose to the growth medium (see *Materials and Methods* for details) to force mitotic exit and trigger Chs2 translocation from the ER to the bud neck in the *dbf2*-mutant cells. This strategy provides the opportunity for assessing the specific effect of Dbf2 inactivation on Chs2 behavior at the division site. As expected, in wild‑type cells, Chs2‑GFP localized, constricted, and disappeared at or from the division site within 12 min ([Figure 6, A and B](#F7){ref-type="fig"}, and Supplemental Video S5, left). In contrast, Chs2‑GFP accumulated at the division site more slowly in the *dbf2*-mutant than in wild‑type cells, perhaps reflecting an imperfect mitotic exit forced by Sic1 overexpression ([Figure 6, A and B](#F7){ref-type="fig"}, and Supplemental Video S5, right). More important, Chs2‑GFP was retained at the division site of the mutant cells for \>40 min with little constriction, and its signal intensity decreased gradually over time ([Figure 6, A and B](#F7){ref-type="fig"}, and Supplemental Video S5, right). The weak signal of Chs2‑GFP at the end of our imaging, coupled with its nearly nonconstrictive behavior, prevented a clear assessment of its constriction symmetry. However, a previous EM study indicates that 81% of the *dbf2* mutant cells form an asymmetric PS ([@B28]), suggesting that Chs2 distribution is eventually asymmetric, which lends strong support to our hypothesis.

![Inactivation of Dbf2 prolongs Chs2 localization at the division site. (A) Chs2 disappears from the division site slowly in a *dbf2* mutant. Wild‑type (WT, *CHS2‑GFP CDC3‑mCherry*; YEF6653) and the *dbf2‑*Ts mutant (*dbf2‑1 dbf20∆ CDC3‑mCherry*, *CHS2‑GFP, pGAL1‑SIC1^s^*; YO1399) cells were grown under conditions to inactivate Dbf2 and also overexpress Sic1 to force mitotic exit in the mutant cells (see *Materials and Methods* for details) and then analyzed by time‑lapse microscopy. (B) Endocytic removal of Chs2 is delayed in the *dbf2* mutant. Quantification of Chs2\*‑GFP disappearance from the division site was performed on the time‑lapse data acquired in A, as well as those acquired from strains YO1410 (*dbf2‑1 dbf20∆ CDC3‑mCherry*, *chs2‑S217A‑GFP, pGAL1‑SIC1^s^*) and YO1411 (*dbf2‑1 dbf20∆ CDC3‑mCherry*, *chs2‑S217D‑GFP, pGAL1‑SIC1^s^*). The average of the peak fluorescence of Chs2\*‑GFP for each strain was set at 100. The error bar represents SEM.](2445fig6){#F6}

![Increased dosage of Cyk3 stimulates Chs2‑dependent chitin synthesis and robustly suppresses the growth and cytokinesis defects of both *chs2‑AA* and *chs2-DD* mutants. (A) Multicopy *CYK3* suppresses the growth defects of *chs2‑AA* and *chs2‑DD.* Strains (YO1543 and YO1544, top half of the plate; YO1550 and YO1551, bottom half of the plate; *chs2∆ Chs2\*-GFP::LEU2 CDC3-mCherry* cells transformed with either an empty vector \[pAG426, *2 μ, URA3*\] or a high‑copy *CYK3* plasmid \[pAG426-CYK3\]) were streaked onto plates containing minimal (SC-URA) or rich (YM-1) media and grown at 25°C for 3--4 d. (B) Multicopy *CYK3* suppresses the cytokinesis defects of *chs2‑AA* and *chs2‑DD.* Cells of different strains (top, YO1245, YO1246, YO1247, and YO1248; bottom, YO1213, YO1214, YO1215, and YO1216; *chs2∆ leu2::LEU2* \[pRS305, vector\] or *chs2∆ Chs2\** (WT, *chs2‑AA,* or *chs2‑DD*)*-GFP::LEU2* cells transformed with either an empty vector \[pRS314\] or a high‑copy *CYK3* plasmid \[pBK42\]) were grown to exponential phase in rich medium (YM-1) at 25°C and then visualized by DIC microscopy. (C) Increased Cyk3 stimulates Chs2‑dependent chitin synthesis at the division site. Cells (YO1129, YO1130; *chs1∆ chs3∆* cells transformed with either an empty vector \[p414ADH\] or a high‑copy *CYK3* plasmid \[pBK42\]) were grown overnight at 30°C on an SC-TRP plate and then stained for cellular chitin using Calcofluor. The relative amounts of chitin in both strains (Vector, n = 14; *CYK3*, n = 22) were quantified and presented in the plot. The average intensity for the strain containing the "Vector" was arbitrarily set at 100. The error bar represents SEM. Scale bar, 2 μm. (D) *chs2‑AA* and *chs2‑DD* mutations display synthetically enhanced defects with *cyk3Δ.* Different strains (top, YO1338, YO1339, YO1450, and YO1451; *chs2∆ leu2::LEU2* \[pRS305, vector\] and *chs2∆ Chs2*\* (WT*, chs2‑AA,* or *chs2‑DD*)*-GFP::LEU2*; bottom, YO1209, YO1210, YO1211, and YO1212; *chs2∆ cyk3∆ leu2::LEU2* \[pRS305, vector\] and *chs2∆ cyk3∆ Chs2\** (WT*, chs2‑AA,* or *chs2‑DD*)*-GFP::LEU2*) were grown to exponential phase in SC-LEU medium at 25°C and then visualized by DIC microscopy. Scale bar, 5 μm.](2445fig7){#F7}

Similar to wild‑type Chs2, Chs2‑S217A and Chs2‑S217D accumulated at and then disappeared from the division site more slowly in the *dbf2*-mutant than in wild‑type cells, although Chs2‑S217D consistently seemed to disappear more quickly ([Figure 6B](#F7){ref-type="fig"}). Together these data suggest that the endocytic removal of Chs2 is delayed in the *dbf2* mutant, which is largely independent of Chs2 phosphorylation by Dbf2. This conclusion is supported by the previous observation that accumulation of actin patches at the division site, which are required for endocytosis in budding yeast, is significantly decreased in the *dbf2* mutant ([@B9]). Thus the MEN may also regulate the endocytic removal of Chs2 during cytokinesis by regulating actin‑patch polarization at the division site.

Cyk3 is a robust dosage suppressor of *chs2* phosphomutants
-----------------------------------------------------------

Cyk3, a cytokinesis protein that localizes to the division site in a Dbf2‑dependent manner ([@B28]), has been implicated in PS formation, but the underlying mechanism remains unknown ([@B19]; [@B33]; [@B28]). It is striking that high‑copy *CYK3* robustly suppressed the growth and cytokinesis defects of both *chs2-AA* and *chs2-DD* cells ([Figure 7, A and B](#F7){ref-type="fig"}). In contrast, high‑copy *CYK3* failed to rescue *chs2∆* cells ([Figure 7B](#F7){ref-type="fig"}), suggesting that the suppression is Chs2 dependent. Of importance, high‑copy *CYK3* strongly stimulated chitin synthesis at the division site of *chs1Δ chs3Δ* cells in which Chs2 is the sole chitin synthase ([Figure 7C](#F7){ref-type="fig"}). Reciprocally, deletion of *CYK3* exacerbated the defects of the *chs2‑AA* and *chs2‑DD* mutants even when the mutant cells were grown in minimal media ([Figure 7D](#F7){ref-type="fig"}). Consistent with the notion of Cyk3 acting through Chs2, *cyk3∆* and *chs2∆* did not produce any additive or synergistic defect in growth or cytokinesis ([Figure 7D](#F7){ref-type="fig"}). Together these data strongly suggest that Cyk3 is an activator of Chs2 in vivo and that Cyk3 and Ser-217 phosphorylation regulate Chs2 function independently during cytokinesis.

DISCUSSION
==========

Dbf2 directly phosphorylates Chs2 to regulate its dynamics and chitin synthesis at the division site during cytokinesis
-----------------------------------------------------------------------------------------------------------------------

Our study demonstrated, for the first time, that Chs2 is a direct substrate of the conserved mitotic exit kinase Dbf2. Chs2 contains six putative Dbf2-consensus sites (RXXS; Ser-21, Ser-150, Ser-217, Ser-225, Ser-256, and Ser-326; [@B24]) at its N‑terminal region and two catalytically important as well as seven predicted transmembrane domains in its C‑terminal region ([Figure 1A](#F1){ref-type="fig"}). In this study, we showed that both Ser-217 and Ser-225 are phosphorylated by Dbf2 in vitro. Of importance, the same two sites were also found to be phosphorylated in vivo in global studies of phosphoproteins in budding yeast ([@B6]; [@B10]). Other putative Dbf2 sites and/or additional serines or threonines in the N‑terminal region of Chs2 may also be phosphorylated by Dbf2, as ∼43% of phosphorylation still remained when GST‑Chs2 (1--286, S217A S225A) was used as the substrate. However, because of the clear phenotypes displayed by the *chs2‑S217* mutations, our functional analysis has thus far focused on phosphorylation at this residue. These results, together with the observations that Chs2 and Dbf2 colocalize at the division site during cytokinesis and that Dbf2 is also implicated in PS formation ([@B28]), make Chs2 a highly likely substrate of Dbf2 in vivo.

Our study suggests that Ser-217 phosphorylation regulates Chs2 dynamics and chitin synthesis at the division site during cytokinesis. Both the phosphodeficient and the phosphomimic mutations of Ser-217 caused little defect in the catalytic activity of Chs2 in the bulk chitin synthase assay in vitro but clearly caused a 30% reduction in chitin synthesis at the division site in vivo. Because the amount and duration of the Chs2‑S217A and Chs2‑S217D variants at the bud neck are similar to those of the wild‑type protein, these data suggest that Ser-217 is involved in fine-tuning the chitin synthase activity of Chs2. This is consistent with previous reports that the N‑terminal noncatalytic region of Chs2, including the Ser-217 residue ([Figure 1A](#F1){ref-type="fig"}), is involved in the regulation of Chs2 activity based on in vitro chitin assays ([@B44]; [@B26]). The underlying mechanism for the involvement of Ser-217 in this regulation remains unknown. One possibility is that Ser-217 might affect the putative proteolysis of Chs2 that is believed to be required for its activation in vivo ([@B37]; [@B44]; [@B26]). However, we note that in our experiments, the *chs2-S217A* and *chs2-S217D* mutations did not significantly affect the degree to which the in vitro Chs2 activity was stimulated by trypsin. The moderate decrease in chitin synthesis caused by both the *chs2‑S217A* and the *chs2‑S217D* mutations in vivo likely explains, at least in part, their medium‑dependent defects in cytokinesis. Presumably, cells demand more robust chitin synthesis at the division site to ensure efficient cytokinesis in the fast‑growing rich media than in the slow‑growing minimal media.

Despite their similar defects in chitin synthesis in vivo, the phosphodeficient and the phosphomimic variants of Chs2 at Ser-217 displayed strikingly different behaviors at the division site, which may also partly account for their defects in cytokinesis. Chs2‑S217A is associated with the AMR throughout cytokinesis. In contrast, Chs2‑S217D is largely uncoupled from the AMR upon its arrival at the division site. These observations suggest a simple model for the function of Ser-217 phosphorylation ([Figure 8A](#F8){ref-type="fig"}). In wild‑type cells, "unphosphorylated" Chs2 is delivered to the division site at the onset of cytokinesis. Approximately halfway through AMR constriction, Dbf2 level reaches its peak at the bud neck, causing phosphorylation of Chs2 at Ser-217, resulting in Chs2 dissociation from the AMR. This dissociation may facilitate Chs2 inactivation and/or its endocytic removal from the division site. Persistent association of Chs2 with the AMR, as shown by Chs2‑S217A, somehow causes asymmetric distribution of the AMR components, resulting in asymmetric constriction. On the other hand, premature uncoupling of Chs2 from the AMR, as shown by Chs2‑S217D, results in broad and dynamic distribution of Chs2‑S217D between the septin rings, which presumably would lead to inefficient PS formation due to inaccurate placement of chitin. Thus timed phosphorylation of Ser-217 is important for proper PS formation and cytokinesis.

![Roles of CDK1 and MEN in the control of Chs2 localization, dynamics, and activation during cytokinesis. (A) Role of Dbf2 in regulating Chs2--AMR association during cytokinesis. (B) Multipronged regulation of Chs2 function by MEN. MEN regulates Chs2 exit from the ER by antagonizing CDK1 phosphorylation, regulates Chs2 dynamics by direct phosphorylation, and stimulates Chs2 activity through Cyk3 by a yet‑to‑be‑defined mechanism. See the text for details.](2445fig8){#F8}

Dbf2 regulates primary septum formation through multiple pathways
-----------------------------------------------------------------

Dbf2 appears to regulate PS formation at multiple levels via distinct mechanisms ([Figure 8B](#F8){ref-type="fig"}). First, during mitosis, Chs2 is phosphorylated by CDK1 at four residues (Ser-14, Ser-60, Ser-69, and Ser-100), and this phosphorylation prevents Chs2 from prematurely exiting the ER before cytokinesis ([@B42]). During mitotic exit, Dbf2, as a part of the MEN, activates the phosphatase Cdc14, which removes the CDK1 phosphorylation from Chs2, thus promoting its exit from the ER ([@B7]). Second, we show here that Dbf2 phosphorylates Chs2 directly at the division site to regulate its chitin synthase activity and also its dissociation from the AMR. This regulatory mechanism plays an important role in cytokinesis. Third, Dbf2 regulates PS formation indirectly by controlling Cyk3 localization to the division site ([@B28]). We show here that increased dosage of Cyk3 stimulates Chs2‑mediated chitin synthesis and robustly suppresses *chs2‑AA* and *chs2‑DD* mutants, whereas deletion of *CYK3* exacerbates the phenotypes of the *chs2* mutants. These data suggest that Cyk3 is a potent activator of Chs2 in vivo and that Cyk3 and Dbf2‑mediated phosphorylation regulate Chs2 function independently during cytokinesis. Fourth, Dbf2 may regulate the endocytic removal of Chs2 from the division site by regulating actin‑patch polarization at the division site. Finally, Dbf2 is also known to phosphorylate the F‑BAR protein Hof1 ([@B27]), which has been implicated in PS formation and/or its coordination with the AMR during cytokinesis ([@B45]; [@B28], [@B27]).

It becomes increasingly clear that ECM remodeling is important for animal cytokinesis ([@B29]; [@B18]). However, how the ECM is locally remodeled at the division site and how this remodeling is coupled to AMR constriction and controlled by the cell cycle machinery remain largely unknown in animal cells. In this study, we established a mechanism by which the conserved mitotic exit kinase Dbf2 directly phosphorylates Chs2 to regulate PS formation (or ECM remodeling) during cytokinesis in budding yeast. On the basis of the overall conservation in the core mechanisms of cell cycle control and cytokinesis between yeast and animal cells, we speculate that similar cell cycle regulation of ECM remodeling during cytokinesis likely exists in animal cells.

MATERIALS AND METHODS
=====================

Strains and growth media
------------------------

Yeast strains used in this study are listed in [Table 1](#T1){ref-type="table"}. Standard culture media and genetic techniques were used ([@B16]). *Escherichia coli* strains DH12S (Invitrogen, Carlsbad, CA) and BL21 (DE3) (Invitrogen) were used as hosts for plasmid manipulation and recombinant protein expression, respectively. Yeast strains were grown routinely at 25°C in synthetic complete (SC) minimal medium lacking specific amino acid(s) and/or uracil or in rich medium YM-1 ([@B20]) or yeast extract/peptone/dextrose (YPD).

###### 

Yeast strains used in this study. Continued

  Strain    Genotype                                                                                                                                 Source
  --------- ---------------------------------------------------------------------------------------------------------------------------------------- ---------------
  J230‑2D   **a** *dbf2‑1 dbf20∆::TRP1 ade1 leu2 trp1 ura3*                                                                                          [@B43])
  YEF473    **a**/α *his3/his3 leu2/leu2 lys2/lys2 trp1/trp1 ura3/ura3*                                                                              [@B4])
  YEF473A   **a** *his3 leu2 lys2 trp1 ura3*                                                                                                         [@B4])
  YEF473B   α *his3 leu2 lys2 trp1 ura3*                                                                                                             [@B4])
  YEF2845   As YEF473 except *chs2∆::His3MX6/CHS2*                                                                                                   This study^a^
  YEF6653   **a** *CHS2-GFP::His3MX6 CDC3-mCherry::URA3*                                                                                             This study
  YO790     **a** *chs1∆::KanMX6 chs3∆::His3MX6*                                                                                                     This study^a^
  YO1111    **a** *chs1∆::NatMX6 chs3∆::His3MX6*                                                                                                     This study
  YO1172    **a**/α *chs2∆::His3MX6/CHS2 chs3∆::KanMX6/CHS3* \[pEC2, 2 μ, *CHS2, URA3*\]                                                             This study
  YO1182    **a** *CHS2-GFP::KanMX6 DBF2-mCherry::His3MX6*                                                                                           This study
  YO1194    α *chs2∆::His3MX6* \[pEC2, 2 μ, *CHS2, URA3*\]                                                                                           This study
  YO1209    **a** *chs2∆::His3MX6 cyk3∆::TRP1 leu2::LEU2‑pRS305*                                                                                     This study
  YO1210    **a** *chs2∆::His3MX6 cyk3∆::TRP1 CHS2-GFP::KanMX6::LEU2*                                                                                This study
  YO1211    **a** *chs2∆::His3MX6 cyk3∆::TRP1 chs2-S217A S225A-GFP::KanMX6::LEU2*                                                                    This study
  YO1212    **a** *chs2∆::His3MX6 cyk3∆::TRP1 chs2-S217D S225D-GFP::KanMX6::LEU2*                                                                    This study
  YO1213    **a** *chs2∆::His3MX6 leu2::LEU2‑pRS305* \[pBK42, 2 μ, *CYK3, TRP1*\]                                                                    This study
  YO1214    **a** *chs2∆::His3MX6 CHS2-GFP::KanMX6::LEU2* \[pBK42, 2 μ, *CYK3, TRP1*\]                                                               This study
  YO1215    **a** *chs2∆::His3MX6 chs2-S217A S225A-GFP::KanMX6::LEU2* \[pBK42, 2 μ, *CYK3, TRP1*\]                                                   This study
  YO1216    **a** *chs2∆::His3MX6 chs2-S217D S225D-GFP::KanMX6::LEU2* \[pBK42, 2 μ, *CYK3, TRP1*\]                                                   This study
  YO1129    **a** *chs1∆::KanMX6 chs3∆::His3MX6* \[p414ADH, *CEN, TRP1*\]                                                                            This study
  YO1130    **a** *chs1∆::KanMX6 chs3∆::His3MX6* \[pBK42, 2 μ, *CYK3, TRP1*\]                                                                        This study
  YO1244    **a** *chs1∆::TRP1 chs2∆::His3MX6 chs3∆::KanMX6* \[pEC2, 2 μ, *CHS2, URA3*\]                                                             This study
  YO1245    **a** *chs2∆::His3MX6 leu2::LEU2‑pRS305* \[pRS314, *CEN, TRP1*\]                                                                         This study
  YO1246    **a** *chs2∆::His3MX6 CHS2-GFP::KanMX6::LEU2* \[pRS314, *CEN, TRP1*\]                                                                    This study
  YO1247    **a** *chs2∆::His3MX6 chs2-S217A S225A-GFP::KanMX6::LEU2* \[pRS314, *CEN, TRP1*\]                                                        This study
  YO1248    **a** *chs2∆::His3MX6 chs2-S217D S225D-GFP::KanMX6::LEU2* \[pRS314, *CEN, TRP1*\]                                                        This study
  YO1320    **a** *chs1∆::TRP1 chs2∆::His3MX6 chs3∆::KanMX6* \[YCp111-CHS2-GFP::KanMX6, *CEN, LEU2*\]                                                This study
  YO1324    **a** *chs1∆::TRP1 chs2∆::His3MX6 chs3∆::KanMX6* \[YCp111-CHS2-S217A‑GFP::KanMX6, *CEN, LEU2*\]                                          This study
  YO1325    **a** *chs1∆::TRP1 chs2∆::His3MX6 chs3∆::KanMX6* \[YCp111-CHS2-S217D-GFP::KanMX6, *CEN, LEU2*\]                                          This study
  YO1338    α *chs2∆::His3MX6 CDC3-mCherry::TRP1 leu2::LEU2‑pRS305*                                                                                  This study
  YO1339    α *chs2∆::His3MX6 CDC3-mCherry::TRP1 CHS2-GFP::KanMX6::LEU2*                                                                             This study
  YO1359    α *chs2∆::His3MX6 CDC3-mCherry::TRP1 chs2‑S217A-GFP::KanMX6::LEU2*                                                                       This study
  YO1360    α *chs2∆::His3MX6 CDC3-mCherry::TRP1 chs2‑S217D-GFP::KanMX6::LEU2*                                                                       This study
  YO1398    **a** *dbf2‑1 dbf20∆::TRP1 CDC3‑mCherry::LEU2*                                                                                           This study^b^
  YO1399    **a** *dbf2‑1 dbf20∆::TRP1 CDC3‑mCherry::LEU2 pGAL1‑SIC1^s^ (T5V, T33V, S76A)‑HA::URA3* \[YCp111‑CHS2‑GFP::KanMX6, *CEN, LEU2*\]         This study
  YO1400    **a** *dbf2‑1 dbf20∆::TRP1 CDC3‑mCherry::LEU2 pGAL1‑SIC1^s^ (T5V, T33V, S76A)‑HA::URA3*                                                  This study
  YO1410    **a** *dbf2‑1 dbf20∆::TRP1 CDC3‑mCherry::LEU2 pGAL1‑SIC1^s^ (T5V, T33V, S76A)‑HA::URA3* \[YCp111‑CHS2‑S217A‑GFP::KanMX6, *CEN, LEU2*\]   This study
  YO1411    **a** *dbf2‑1 dbf20∆::TRP1 CDC3‑mCherry::LEU2 pGAL1‑SIC1^s^ (T5V, T33V, S76A)‑HA::URA3* \[YCp111‑CHS2‑S217D‑GFP::KanMX6, *CEN, LEU2*\]   This study
  YO1450    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217A S225A-GFP::KanMX6::LEU2*                                                                    This study
  YO1451    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217D S225D-GFP::KanMX6::LEU2*                                                                    This study
  YO1454    α *chs2∆::His3MX6 CHS2-GFP::KanMX6::LEU2* \[pRS314-MYO1-C-mCherry, *CEN, TRP1*\]                                                         This study
  YO1453    α *chs2∆::His3MX6 chs2-S217A S225A-GFP::KanMX6::LEU2* \[pRS314-MYO1-C-mCherry, *CEN, TRP1*\]                                             This study
  YO1455    α *chs2∆::His3MX6 chs2-S217D S225D-GFP::KanMX6::LEU2* \[pRS314-MYO1-C-mCherry, *CEN, TRP1*\]                                             This study
  YO1528    **a** *chs1∆::NatMX6 chs3∆::His3MX6* \[pRS314, *CEN, TRP1*\]                                                                             This study
  YO1535    **a** *chs1∆::NatMX6 chs3∆::His3MX6* \[YEp-TRP1-pGAL1-HA3-CHS2, 2 μ, *URA3*\]                                                            This study
  YO1536    **a** *chs1∆::NatMX6 chs3∆::His3MX6* \[YEp-TRP1-pGAL1-HA3-CHS2-S217A, 2 μ, *URA3*\]                                                      This study
  YO1537    **a** *chs1∆::NatMX6 chs3∆::His3MX6* \[YEp-TRP1-pGAL1-HA3-CHS2-S217D, 2 μ, *URA3*\]                                                      This study
  YO1543    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217A S225A-GFP::KanMX6::LEU2* \[pAG426, 2 μ, *URA3*\]                                            This study
  YO1544    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217A S225A-GFP::KanMX6::LEU2* \[pAG426-CYK3, 2 μ, *URA3*\]                                       This study
  YO1550    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217D S225D-GFP::KanMX6::LEU2* \[pAG426, 2 μ, *URA3*\]                                            This study
  YO1551    α *chs2∆::HIS3 CDC3-mCherry::TRP1 chs2-S217D S225D-GFP::KanMX6::*LEU2 \[pAG426-CYK3, 2 μ, *URA3*\]                                       This study

^a^All YEF and YO strains except YO1398‑1411 are derived from YEF473, YEF473A, or YEF473B.

^b^Derived from J230‑2D.

Constructions of plasmids and yeast strains
-------------------------------------------

Common plasmid vectors used in this study include YCplac111 (*CEN*, *LEU2*), pRS314 (*CEN*, *TRP1*), pRS316 (*CEN*, *URA3*), pRS305 (integrative, *LEU2*), and YIplac204 (integrative, *TRP1*). Plasmids p414ADH (*CEN, TRP1*; [@B31]) and pBK42 (2μ, *CYK3, TRP1*; [@B19]) were described previously. Plasmid YIplac211‑GAL1‑SIC1^s^ (T5V, T33V, S76A)‑HA (integrative, *URA3*; [@B28]; kindly supplied by Gislene Pereira, German Cancer Research Center, Heidelberg, Germany), carrying a *GAL1* promoter--controlled allele of *SIC1^s^* that encodes a stabilized protein, was cut with *Eco*RV and integrated at the *ura3* locus of the recipient strain. Plasmids YIplac128‑CDC3‑mCherry (integrative, *LEU2*; [@B15]), YIplac211‑CDC3‑mCherry (integrative, *URA3*; [@B12]), and YIplac204-CDC3-mCherry (integrative, TRP1; [@B47]), carrying mCherry‑tagged *CDC3*, were digested with *Bgl*II and integrated at the *CDC3* locus of the recipient strains. Plasmid pGEX5X‑CHS2‑N was constructed by cloning a *Bam*HI- and *Sal*I-digested (both sites were introduced in PCR primers) *CHS2* fragment encoding amino acids 1--286 into the corresponding sites of pGEX5X-1 (GE Healthcare, Pittsburgh, PA). YEp-pGAL1-HA3-CHS2 was constructed by inserting a 1.7-kb PCR fragment carrying *TRP1‑pGAL1‑HA3* ([@B23]) in front of *CHS2* on plasmid pEC2 (2 μ, *CHS2, URA3*; [@B13]). The QuikChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) was used to generate phosphodeficient mutations (S217A and/or S225A) or phosphomimic mutations (S217D and/or S225D) in *CHS2* using plasmid YCp111-CHS2-GFP‑KanMX6 as the template ([@B47]). Wild‑type and the phosphomutant alleles of *CHS2* were then subcloned into the integrative vector pRS305 (*LEU2*), as described previously ([@B47]). The resulting plasmid pRS305‑CHS2\*‑GFP was digested with *Afl*II and integrated at the *leu2* locus of the recipient strains. Plasmid pAG24‑CYK3 was constructed by transferring *CYK3* from the tiling library plasmid pGP564-CYK3 (2 μ, *LEU2*; Open Biosystems, Lafayette, CO) onto the Gateway vector pAG24 (2 μ, *URA3*) using Gateway LR Clonase II (Invitrogen, Grand Island, NY).

Microscopy
----------

A computer-controlled Eclipse 800 microscope (Nikon, Tokyo, Japan) and a high-resolution charge-coupled device camera (model C4742-95; Hamamatsu Photonics, Bridgewater, NJ) were used to visualize cell morphology, Calcofluor‑stained chitin ([@B36]), and *CHS2\*‑GFP* (wild-type \[WT\] or phosphomutant alleles of *CHS2*) by differential interference contrast (DIC) and fluorescence microscopy, respectively. The images were acquired using Image-Pro Plus version 7.0 (Media Cybernetics, Bethesda, MD).

For live‑cell imaging of yeast strains carrying a plasmid, cells were grown at 25°C in SC media lacking a specific amino acid to select for the presence of a plasmid. For imaging yeast strains carrying a *chs2* phosphomutation, cells were first grown in SC‑LEU medium to keep them healthy and then washed twice with rich medium YM-1 without carbon source. Cells were then incubated further for 1--3 h at 25°C before being concentrated by centrifugation and spotted on a slab of YM-1 medium containing 2% agarose for live‑cell imaging. For live‑cell imaging at 37°C ([Figure 6](#F6){ref-type="fig"}), the wild‑type and the *dbf2‑1 dbf20∆* strains were grown in liquid YM‑1 media containing 2% raffinose at 25°C to the exponential phase and then shifted to 37°C for additional 3 h. A 2.0‑ml culture was then transferred to a 3.5‑mm dish coated with polylysine (MatTek, Ashland, MA), which was incubated in the 37°C chamber of the microscope for 20 min to let the cells settle down. A 1.5‑ml culture was then removed from the dish, which was followed by the addition of a 1.5‑ml prewarmed YM-1 medium containing 2% raffinose, 3% galactose, and 1.5% low‑melting agarose. Images were acquired at 25 or 37°C on a spinning disk confocal microscope equipped with a Yokogawa CSU 10 scan head combined with an Olympus IX 71 microscope (Olympus, Tokyo, Japan) and an Olympus 100× objective (1.4 numerical aperture, Plan S-Apo oil immersion). Acquisition and hardware were controlled by MetaMorph, version 7.7 (Molecular Devices, Downingtown, PA). A Hamamatsu ImagEM EMCCD camera (model C9100-13, Bridgewater, NJ) was used for capture. Diode lasers for excitation (488 nm for GFP and 561 nm for mCherry/RFP) were housed in a launch constructed by Spectral Applied Research (Richmond Hill, Canada). Images were taken every minute with *z*‑stacks ranging from 11 × 0.3 to 12 × 0.5 μm. A maximum projection was generated with MetaMorph, version 7.7, or ImageJ (1.45b; National Institutes of Health, Bethesda, MD). For quantification of relative chitin levels in different *chs2* phosphomutants ([Figure 3](#F3){ref-type="fig"}), the ratio between Calcofluor signal intensity at the bud neck was divided by Chs2-GFP signal intensity at the bud neck.

For the experiments involving FRAP, cells were grown to exponential phase in SC-HIS media at 23°C. Cells were then centrifuged and resuspended in 10 ml YM-1 medium and grown for at least another 3 h in a 50‑ml flask at 25°C in a water‑bath shaker. One milliliter of this culture was taken to concentrate the cells by centrifugation. Cells were then spotted on YM-1 medium containing 2% agarose for FRAP and imaging analysis. FRAP was performed using a Micro­Point computer-controlled ablation system (Photonic Instruments, St. Charles, IL) consisting of a nitrogen-pumped dye laser (wavelength, 435 nm) controlled by MetaMorph. In some cases, sequential photobleaching was applied ([Figure 5A](#F5){ref-type="fig"}, S217D). Images were captured and processed using the same microscope, camera, and software as described earlier. Images were taken every 20 s with a *z*-stack consisting of 12 × 0.4 μm steps.

Kinase assay
------------

GST-Chs2(1-286; WT, S217A, or S217D) fusion proteins were expressed in the *E. coli* strain BL21 (DE3) and purified as described previously ([@B12]). Dbf2-dependent phosphorylation of GST-Chs2(1-286) was performed as described previously ([@B30]).

In vitro assay for Chs2 activity
--------------------------------

Cells (YO1528, YO1535, YO1536, and YO1537) were grown for 24 h at 30°C in 30 ml of SC medium supplemented with tryptophan and lysine. Cells were sedimented by centrifugation and then resuspended in 250 ml 0.67% (wt/vol) yeast nitrogen base containing 2% (wt/vol) galactose, 1% (wt/vol) raffinose, tryptophan, and lysine. These cultures were incubated for 18 h at 25°C. Mixed membranes were prepared as described previously ([@B34]) with several slight modifications. Induced cultures were harvested, and cells were washed once with 12 ml of cold water and once with 10 ml of cold 30 mM Tris-HCl (pH 7.5). All subsequent steps were carried out on ice. Cells were broken by vortexing with glass beads in 30 mM Tris-HCl (pH 7.5), the beads were then washed with 30 mM Tris-HCl (pH 7.5), and cell walls and unbroken cells were sedimented by low-speed centrifugation. The pellet was washed once with 30 mM Tris-HCl (pH 7.5), and the combined wall-free supernatants (10 ml) were sedimented by centrifugation at 100,000 × *g* for 45 min at 4°C. Mixed membranes were then homogenized in cold 30 mM Tris-HCl (pH 7.5) and then sedimented again at 100,000 × *g.* The washed membranes were homogenized in 0.9 ml of cold 30 mM Tris-HCl (pH 7.5) containing 33% (vol/vol) glycerol and then frozen at --80°C. Protein contents of membranes were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). Trypsin treatment was carried out on 100-μl portions of mixed membranes by adding 3 μl of solutions containing 100 or 200 μg of trypsin (Sigma‑Aldrich, St. Louis, MO) in 30 mM Tris-HCl (pH 7.5). After incubation at 30°C for 10 min, trypsin digestion was stopped by adding 3 μl of solutions containing an amount of soybean trypsin inhibitor (Sigma‑Aldrich) double the amount of trypsin used. As no-trypsin controls, samples of membranes were incubated in parallel with buffer alone for 10 min at 30°C, after which 3 μl of a solution containing 200 μg of trypsin inhibitor was added. The treated membranes were then placed on ice and assayed forthwith. Assay mixtures contained, in a final volume of 50 μl, 2 mM UDP GlcNAc, UDP-\[14C(U)\] GlcNAc (specific activity, 300 mCi/mmol, 61,000 cpm per incubation \[American Radiolabeled Chemicals, St. Louis, MO\]), 32 mM GlcNAc, and 2.5 mM cobalt acetate. Reactions were started by the addition of 20 μl of trypsin-treated or control membranes (typically containing ∼400 μg of membrane proteins) and terminated by the addition of 1 ml of cold 10% (wt/vol) trichloroacetic acid. Insoluble radioactivity was collected by filtration on GF/C discs, and the filters were washed as described previously ([@B34]).
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AMR

:   actomyosin ring

ECM

:   extracellular matrix

PS

:   primary septum
